CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 180 enrolled
Drug / intervention
Meningococcal ACWY conjugate vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01547715
NCT01547715Phase 3Completed
CompareCT.gov

A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 75 Years of Age in India.

Novartis·interventional·Posted Mar 8, 2012·Updated Oct 9, 2018

In Brief

A Phase 3 clinical trial evaluating Meningococcal ACWY conjugate vaccine for Bacterial Meningitis. Completed, enrolled 180 participants across 4 sites.

Detailed Summary

This study will evaluate the immunogenicity of a single injection of Novartis Meningococcal ACWY conjugate vaccine in healthy subjects from the age of 2 years and above in India.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Meningitis
CountriesIndia
CollaboratorsNovartis Vaccines

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 8, 2012
Enrollment StartMar 1, 2012
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.3 years ago

Interventions

Meningococcal ACWY conjugate vaccinebiological

All subjects received a single dose of Meningococcal ACWY conjugate vaccine